Page 73 - IJB-10-6

International Journal of Bioprinting Semi-solid extrusion for pediatric medicine

129. Elbadawi M, Gustaffson T, Gaisford S, Basit AW. 3D 139. Section 503A of the Federal Food, Drug, and Cosmetic Act.
printing tablets: predicting printability and drug FDA; 2018. Accessed April 12, 2024.
dissolution from rheological data. Int J Pharm. 2020; https://www.fda.gov/drugs/human-drug-compounding/
590:119868. section-503a-federal-food-drug-and-cosmetic-act
doi: 10.1016/j.ijpharm.2020.119868 140. Beitler BG, Abraham PF, Glennon AR, et al. Interpretation
130. Suárez-González J, Díaz-Torres E, Monzón-Rodríguez of regulatory factors for 3D printing at hospitals and medical
CN, Santoveña-Estévez A, Fariña JB. Revolutionizing centers, or at the point of care. 3D Print Med. 2022;8(1):7.
three-dimensional printing: enhancing quality assurance doi: 10.1186/s41205-022-00134-y
and point-of-care integration through instrumentation. 141. Jørgensen AK, Ong JJ, Parhizkar M, Goyanes A, Basit
Pharmaceutics. 2024;16(3):408. AW. Advancing non-destructive analysis of 3D printed
doi: 10.3390/pharmaceutics16030408 medicines. Trends Pharmacol Sci. 2023;44(6):379-393.
131. Khaled SA, Burley JC, Alexander MR, Yang J, Roberts CJ. 3D doi: 10.1016/j.tips.2023.03.006
printing of tablets containing multiple drugs with defined 142. Miller GF, Coffield E, Leroy Z, Wallin R. Prevalence and
release profiles. Int J Pharm. 2015;494(2):643-650. costs of five chronic conditions in children. J Sch Nurs Off
doi: 10.1016/j.ijpharm.2015.07.067 Publ Natl Assoc Sch Nurses. 2016;32(5):357-364.
132. Haring AP, Tong Y, Halper J, Johnson BN. Programming doi: 10.1177/1059840516641190
of multicomponent temporal release profiles in 143. Bg PK, Mehrotra S, Marques SM, Kumar L, Verma R. 3D
3D printed polypills via core–shell, multilayer, and printing in personalized medicines: a focus on applications
gradient concentration profiles. Adv Healthc Mater. of the technology. Mater Today Commun. 2023;35:105875.
2018;7(16):1800213. doi: 10.1016/j.mtcomm.2023.105875
doi: 10.1002/adhm.201800213
144. ClinicalTrials.gov. Metronomic Chemotherapy in Wilms
133. Borges AF, Silva C, Coelho JFJ, Simões S. Outlining Tumor (MetroWilms-1906) (MetroWilms); 2022. Accessed
critical quality attributes (CQAs) as guidance for the April 30, 2024.
development of orodispersible films. Pharm Dev Technol. https://classic.clinicaltrials.gov/ct2/show/NCT05384821
2017;22(2):237-245.
doi: 10.1080/10837450.2016.1199567 145. Binson G, Sanchez C, Waton K, et al. Accuracy of dose
administered to children using off-labelled or unlicensed
134. El Aita I, Breitkreutz J, Quodbach J. On-demand oral dosage forms. Pharmaceutics. 2021;13(7):1014.
manufacturing of immediate release levetiracetam tablets doi: 10.3390/pharmaceutics13071014
using pressure-assisted microsyringe printing. Eur J Pharm
Biopharm. 2019;134:29-36. 146. Curti C, Brandin T, Kabac T, et al. Contrôle qualité
doi: 10.1016/j.ejpb.2018.11.008 des préparations magistrales en officine: contraintes
réglementaires et pistes d’amélioration. Pharm Hosp Clin.
135. Pluta P. Compounding overview: primary considerations for 2020;55(3):268-274.
the workplace. Pharm Technol. 2024;48(2):18-22. Accessed doi: 10.1016/j.phclin.2020.04.009
April 10, 2024.
https://www.pharmtech.com/view/compounding- 147. Zheng Z, Lv J, Yang W, et al. Preparation and application
overview-primary-considerations-for-the-workplace of subdivided tablets using 3D printing for precise hospital
dispensing. Eur J Pharm Sci. 2020;149:105293.
136. European Medicines Agency. ICH guideline Q10 on doi: 10.1016/j.ejps.2020.105293
pharmaceutical quality system; 2007.
https://www.ema.europa.eu/en/documents/scientific- 148. Cui M, Pan H, Fang D, Sun H, Qiao S, Pan W. Exploration
guideline/international-conference-harmonisation- and evaluation of dynamic dose-control platform for
technical-requirements-registration-pharmaceuticals- pediatric medicine based on Drop-on-Powder 3D printing
human_en.pdf technology. Int J Pharm. 2021;596:120201.
doi: 10.1016/j.ijpharm.2021.120201
137. European Medicines Agency. ICH guideline Q8 (R2) on
pharmaceutical development; 2004. 149. Park BJ, Choi HJ, Moon SJ, et al. Pharmaceutical applications
https://www.ema.europa.eu/en/documents/scientific- of 3D printing technology: current understanding and
guideline/international-conference-harmonisation- future perspectives. J Pharm Investig. 2019;49:575-585.
technical-requirements-registration-pharmaceuticals- doi: 10.1007/s40005-018-00414-y
human-use_en-11.pdf 150. de Groot MCH, van Puijenbroek EP. Clindamycin and taste
disorders. Br J Clin Pharmacol. 2007;64(4):542-545.
138. Seoane-Viaño I, Xu X, Ong JJ, et al. A case study on
decentralized manufacturing of 3D printed medicines. doi: 10.1111/j.1365-2125.2007.02908.x
Int J Pharm X. 2023;5:100184. 151. Shinotsuka H, Mizutani N, Aikawa S, Kimura G. Palatability
doi: 10.1016/j.ijpx.2023.100184 evaluation of sulfamethoxazole/trimethoprim with

Volume 10 Issue 6 (2024) 65 doi: 10.36922/ijb.4063